The Clinical Relevance of the Expression of Several Multidrug-Resistant-Related Genes in Patients with Primary Acute Myeloid Leukemia

REFERENCES

• Juranka P, Zastawny R, Ling V. P-glycoprotein: mul-tidrug resistance and a superfamily of membrane associated transport proteins. FASEB J 1989; 3 (14): 2582–2585.
   Web of Science ®Google Scholar
• Zochbauer S, Gsur A, Brunner R, Kyrie PA, Lechner K, Pirker R. P-glycoprotein expression is unfavorable prognostic factor in acute myeloid leukemia. Leukemia 1994; 8 (6): 974–977.
   PubMed Web of Science ®Google Scholar
• Venditti A, Tamburini A, Buccisano F, et al. Clinical rel-evance of minimal residual disease detection in adult acute myeloid leukemia. J Hematother Stem Cell Res 2002; 11 (2): 349–357.
   PubMedGoogle Scholar
• Lautier D, Canitrot Y, Deeley RG, Cole SP. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 1996; 52 (7): 967–977.
   PubMed Web of Science ®Google Scholar
• Laupeze B, Amiot L, Drenou B, et al. High multidrug resistance protein activity in acute myeloid leukaemias is asso-ciated with poor response to chemotherapy and reduced patient survival. Br J Haematol 2002; 116 (4): 834–838.
   PubMed Web of Science ®Google Scholar
• Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a 110,000 vescicular protein in non-P-gly-coprotein-mediated multidrug resistance. Cancer Res 1993; 53 (7): 1475–1479.
   PubMed Web of Science ®Google Scholar
• Giesler F, Glasmacher A, Kampfe D, et al. Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotox-ines. Leukemia 1996; 10 (Suppl 3): S46–S49.
   PubMedGoogle Scholar
• Voso MT, D'Alo' F, Putzulu R, et al. Negative prognos-tic value of glutathione 5-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 2002; 100 (8): 2703–2707.
   PubMed Web of Science ®Google Scholar
• Pirker R, Wallner J, Geissler K, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Nat Cancer Inst 1991; 83 (10): 708–712.
   PubMed Web of Science ®Google Scholar
• Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute non lymphoblastic leukemia cells at diagnosis. Blood 1992; 79 (2): 473–476.
   PubMed Web of Science ®Google Scholar
• List A, Spier CS, Grogan TM, et al. Overexpression of the major vault transporter protein lung-resistance protein pre-dicts treatment outcome in acute myeloid leukemia. Blood 1996; 87 (6): 2464–2469.
   PubMed Web of Science ®Google Scholar
• Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH. Multidrug resistance-associated protein gene over-expression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF-7 cell line selected for etopo-side resistance. Cancer Res 1994; 54 (1): 152–158.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schoester M, Smith E, Lowenberg B. Expression of the multidrug resistance phenotype mdrl but not mrp is the single most important prognostic factor in elderly patients with acute myeloid leukemia. Br J Haematol 1996; 93 (Suppl. 2): 141.
   Google Scholar
• Bennet JM, Catovsky D, Daniel MT, Flaudring G, Gralnick HR, Sultan C. Proposed revised criteria for the classi-fication of acute myeloid leukemia. A report of the French, American-British Cooperative Group. Ann Inter Med 1985; 103 (4): 620–625.
   PubMed Web of Science ®Google Scholar
• Rowley JD, Potter D. Chromosome binding patterns in acute non-lymphoblastic leukemia. Blood 1976; 47 (5): 705–721.
   PubMed Web of Science ®Google Scholar
• Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D, Gekeler V. Expression of mdrl, mrp, topoiso-merase II a and 13 and cyclin A in primary or relapsed states of acute lymphoblastic leukemias. Br J Haematol 1995; 89 (2): 356–363.
   PubMed Web of Science ®Google Scholar
• Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD. Quantitative analysis of the MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reac-tion. Proc Nati Acad Sci USA 1990; 87 (18): 7160–7164.
   PubMed Web of Science ®Google Scholar
• Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS. Analysis of multidrug resistance-associated protein (MRP) messanger RNA and malignant hemopoietic cells. Cancer Res 1994; 54 (17): 4676–4679.
   PubMed Web of Science ®Google Scholar
• Hao XY, Widesten M, Ridderstrom M, Hellman U, Mannarvik B. Co-variation of glutathione transferase expres-sion and cytostatic drug resistance in HeLa cells: establishe-ment of class Mu-glutathione transferase M3-3 as the dominat-ing isoenzyme. Biochem J 1994; 297 (Ptl): 59-67.
   Google Scholar
• Izquierdo MA, Shoemaker RH, Flens MJ, et al. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 1996; 65 (2): 230–237.
   PubMed Web of Science ®Google Scholar
• Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 1994; 54 (18): 4833–4836.
   PubMed Web of Science ®Google Scholar
• Beck J, Niethammer D, Gekeler V. High mdrl- and mrp-, but low topoisomerase II alpha-gene expression in B-cell chronic lymphocytic leukaemias. Cancer Lett 1994; 86 (1): 135–42.
   PubMed Web of Science ®Google Scholar
• Borg AG, Burgess R, Green LM, Scheper RJ, Liu Yin JA. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells. Br J Haematol 2000; 108 (1): 48–54.
   PubMed Web of Science ®Google Scholar
• Lohri A, van Hille B, Bacchi M, et al. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-asso-ciated protein, glutathione-S-transferase, bcl-2 and topoiso-merase IIalpha) in 57 newly diagnosed acute myeloid. Eur J Haematol 1997; 59 (4): 206–215.
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Thomas X, Calvo F, et al. In vivo mech-anisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 2002; 117 (4): 860–868.
   PubMed Web of Science ®Google Scholar
• Petrini M, Mattii L, Valentini P, Sabbatini ARM, Grassi B, Grandi M. Idarubicin is active on MDR cells : evaluation of DNA synthesis inhibition on P388 cell lines. Ann Hematol 1993; 67 (5): 227–230.
   PubMed Web of Science ®Google Scholar
• Berman E, Heller G, Santorsa J, et al. Results of a ran-domized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77 (8): 1666–1674.
   PubMed Web of Science ®Google Scholar